ORIC Pharmaceuticals partnered with Cancer Research UK to fully fund and execute early clinical development of ORIC-259, a first-in-class CIP2A mRNA degrader. ORIC retains an option to reacquire rights after Phase 1/2 data.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
